Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3048% above fair value
$0.91−0.08 (-7.64%)
Close on Nov 13, 2026Market cap $231.31MP/E –Yield –
Lineage Cell Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Lineage Cell Therapeutics's EV/EBITDA was 1.2× on Oct 31, 2023.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Oct 31, 2023 | 1.2× | +0.7 |
| 2022 | Dec 30, 2022 | 0.5× | – |
See a number that looks wrong?